Show simple item record

dc.contributor.authorHarrington, KD
dc.contributor.authorLim, YY
dc.contributor.authorAmes, D
dc.contributor.authorHassenstab, J
dc.contributor.authorLaws, SM
dc.contributor.authorMartins, RN
dc.contributor.authorRainey-Smith, S
dc.contributor.authorRobertson, J
dc.contributor.authorRowe, CC
dc.contributor.authorSalvado, O
dc.contributor.authorDoré, V
dc.contributor.authorVillemagne, VL
dc.contributor.authorSnyder, PJ
dc.contributor.authorMasters, CL
dc.contributor.authorMaruff, P
dc.date.accessioned2020-12-17T03:17:25Z
dc.date.available2020-12-17T03:17:25Z
dc.date.issued2017
dc.identifierpii: S2352-8729(17)30036-2
dc.identifier.citationHarrington, K. D., Lim, Y. Y., Ames, D., Hassenstab, J., Laws, S. M., Martins, R. N., Rainey-Smith, S., Robertson, J., Rowe, C. C., Salvado, O., Doré, V., Villemagne, V. L., Snyder, P. J., Masters, C. L. & Maruff, P. (2017). Amyloid β-associated cognitive decline in the absence of clinical disease progression and systemic illness.. Alzheimers Dement (Amst), 8 (1), pp.156-164. https://doi.org/10.1016/j.dadm.2017.05.006.
dc.identifier.issn2352-8729
dc.identifier.urihttp://hdl.handle.net/11343/254822
dc.description.abstractINTRODUCTION: High levels of amyloid β (Aβ) are associated with cognitive decline in cognitively normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individuals who did not progress to mild cognitive impairment or dementia. METHOD: Cognition was measured over 72 months and compared between low (Aβ-) and high (Aβ+) CN older adults (n = 335) who did not progress to mild cognitive impairment or dementia and who remained free of severe or uncontrolled systemic illness. RESULTS: Compared to the Aβ- group, the Aβ+ group showed no cognitive impairment at baseline but showed substantial decline in verbal learning, episodic memory, and attention over 72 months. DISCUSSION: Moderate cognitive decline, particularly for learning and memory, was associated with Aβ+ in CN older adults in the absence of clinical disease progression and uncontrolled or serious comorbid illness.
dc.languageeng
dc.publisherWiley
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.titleAmyloid β-associated cognitive decline in the absence of clinical disease progression and systemic illness.
dc.typeJournal Article
dc.identifier.doi10.1016/j.dadm.2017.05.006
melbourne.affiliation.departmentFlorey Department of Neuroscience and Mental Health
melbourne.affiliation.departmentAnatomy and Neuroscience
melbourne.affiliation.departmentBusiness & Economics
melbourne.affiliation.departmentMedicine (Austin & Northern Health)
melbourne.affiliation.departmentPsychiatry
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.affiliation.facultyBusiness & Economics
melbourne.source.titleAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
melbourne.source.volume8
melbourne.source.issue1
melbourne.source.pages156-164
dc.rights.licenseCC BY-NC-ND
melbourne.elementsid1223902
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520957
melbourne.contributor.authorLim, Yen Ying
melbourne.contributor.authorAmes, David
melbourne.contributor.authorRowe, Christopher
melbourne.contributor.authorVillemagne, Victor
melbourne.contributor.authorMasters, Colin
melbourne.contributor.authorMaruff, Paul
melbourne.contributor.authorHarrington, Karra
melbourne.contributor.authorRobertson, Joanne
dc.identifier.eissn2352-8729
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record